间充质干细胞治疗炎性肠病的研究进展  

Research on mesenchymal stem cells in the treatment of inflammatory bowel disease

作　　者：昝慧[1] 钟英强[1] 

机构地区：[1]中山大学孙逸仙纪念医院消化内科,510120

出　　处：《新医学》2011年第4期211-214,共4页Journal of New Medicine

摘　　要：炎性肠病(IBD)是一种病因不明确的疾病,有终生复发的倾向,重症患者迁延不愈,预后不良。IBD的传统治疗方式主要是运用抗炎和免疫抑制药物,长期治疗易致较多不良反应、效果欠佳。间充质干细胞(MSCs)具有多向分化能力和免疫调节功能,用于治疗IBD具有一定的理论和实验基础,是一种有前途的新型治疗方法。该文主要介绍MSCs移植治疗IBD的应用及其可能的机制。Various theories have been developed to explain the etiopathogenesis of inflammatory bowel disease（IBD）,but so far none of them has led to a therapy with long-term efficacy and without side effects.Current therapies ranging from anti-inflammatory drugs to immunosuppressive regimens,remain inadequate.With the development of research on stem cells,some progress has been achieved in the application of stem cell transplantation to the treatment of IBD.This article mainly introduced the application of mesenchymal stem cell（MSCs） transplantation in the treatment of IBD and the possible mechanism of this novel therapy.

关 键 词：炎性肠病 间充质干细胞 移植 

分 类 号：R574.62[医药卫生—消化系统]